|Last Price||Today's Change||52-Week Range||Trading Volume|
|38.25||-31.68 (-45.30%)||37.43 - 77.31||7.9 million (Above Avg)|
Market data as of 11:31AM 07/01/15. Quotes are delayed by at least 15 min.
MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
06/25/2015 3:18 PM ET
U.S. FDA Grants Priority Review for MM-398 New Drug Application
06/25/2015 7:00 AM ET